StockData
InflaRx N.V. logo

InflaRx N.V. (IFRX) stock

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30
$1.17−0.07 (-5.65%)

Close on Nov 13, 2026Market cap $84.58MP/E –Yield –

InflaRx r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €25.72M, down 27.3% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is €44.58M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€25.72M-27.3%
FY2024Dec 31, 2024€35.36M-13.8%
FY2023Dec 31, 2023€41.02M+9.3%
FY2022Dec 31, 2022€37.53M+5.1%
FY2021Dec 31, 2021€35.70M+39.0%
FY2020Dec 31, 2020€25.68M-42.4%
FY2019Dec 31, 2019€44.58M+78.1%
FY2018Dec 31, 2018€25.03M+73.6%
FY2017Dec 31, 2017€14.41M+173.1%
FY2016Dec 31, 2016€5.28M+51.8%
FY2015Dec 31, 2015€3.48M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025€7.20M-36.3%
Q2 FY2024Jun 30, 2024€10.02M-19.8%
Q2 FY2023Jun 30, 2023€10.92M+117.0%
Q2 FY2022Jun 30, 2022€11.18M–
Q2 FY2021Jun 30, 2021€11.30M–
Q2 FY2019Jun 30, 2019€12.50M–
Q2 FY2018Jun 30, 2018€5.03M–

More InflaRx figures

See a number that looks wrong?